枸橼酸莫沙必利含结晶水 | 636582-62-2

• 物质功能分类: 原料药 - 消化系统用药 - 止吐催吐药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 枸橼酸莫沙必利含结晶水
• 中文别名: 枸橼酸莫沙必利而水合物；枸橼酸莫沙必利水合物；莫沙必利柠檬酸盐二水合物
• 英文名称: 4-Amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]benzamide 2-Hydroxy-1,2,3-propanetricarboxylate Hydrate
• 英文别名: 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide;2-hydroxypropane-1,2,3-tricarboxylic acid;hydrate
• CAS: 636582-62-2
• 化学式: C27H35ClFN3O11
• 分子量: 632.0
• InChiKey: SLDCUFRDADJSBX-UHFFFAOYSA-N

物化性质

• 熔点：
  112-114°C
• 溶解度：
  二甲基亚砜：≥5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1.02
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  210
• 氢给体数：
  7
• 氢受体数：
  14

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R41
• WGK Germany：
  3

制备方法与用途

适应症用于缓解慢性胃炎伴有的消化系统症状，如烧心、早饱、上腹胀、上腹痛、恶心和呕吐。

文献信息

• FILM PREPARATION CONTAINING MEDICAMENT WITH UNPLEASANT TASTE
  申请人：Kyukyu Pharmaceutical Co., Ltd.

  公开号：EP2543366A1

  公开（公告）日：2013-01-09

  Provided is a film preparation in which an unpleasant taste derived from a medicament is masked. The film preparation includes coating layers containing no terpene formed on both sides of a medicament-containing layer containing a medicament having an unpleasant taste and a terpene.

  本发明提供了一种薄膜制剂，可掩盖来自药物的难闻味道。薄膜制剂包括在含有难闻味道的药物和萜烯的含药层两侧形成的不含萜烯的涂层。
• RAPID ALLERGY TESTING METHOD
  申请人：Shibaguchi, Hirotomo

  公开号：EP2975403A1

  公开（公告）日：2016-01-20

  The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient. The method may comprise the steps of causing migration of leukocytes separated from a healthy human or cells of an established cell line with a chemotactic factor contained in a sample such as body fluid or blood of the patient to be tested or a sample stimulated with the agent that may be allergenic to the patient and analyzing the cell kinetics such as migration velocity, migration distance, and migration direction.

  本发明提供了一种检测过敏的方法，能够快速、高度准确地检测过敏反应。该方法可确定患者是否有过敏症，或确定可能对患者有过敏性的制剂是否对患者有过敏性（过敏反应性）。该方法可包括以下步骤：使从健康人或已建立的细胞系的细胞中分离出来的白细胞与待测样本（如患者的体液或血液）或用患者可能过敏的制剂刺激的样本中含有的趋化因子发生迁移，并分析细胞动力学，如迁移速度、迁移距离和迁移方向。
• Method for rapid testing allergy
  申请人：Shibaguchi Hirotomo

  公开号：US10324079B2

  公开（公告）日：2019-06-18

  The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient. The method may comprise the steps of causing migration of leukocytes separated from a healthy human or cells of an established cell line with a chemotactic factor contained in a sample such as body fluid or blood of the patient to be tested or a sample stimulated with the agent that may be allergenic to the patient and analyzing the cell kinetics such as migration velocity, migration distance, and migration direction.

  本发明提供了一种检测过敏的方法，能够快速、高度准确地检测过敏反应。该方法可确定患者是否有过敏症，或确定可能对患者有过敏性的制剂是否对患者有过敏性（过敏反应性）。该方法可包括以下步骤：使从健康人或已建立的细胞系的细胞中分离出来的白细胞与待测样本（如患者的体液或血液）或用患者可能过敏的制剂刺激的样本中含有的趋化因子发生迁移，并分析细胞动力学，如迁移速度、迁移距离和迁移方向。
• Composite preparation of mosapride and rabeprazole
  申请人：KOREA UNITED PHARM. INC.

  公开号：US11000481B2

  公开（公告）日：2021-05-11

  The present invention relates to a composite preparation with various dosage forms comprising mosapride and rabeprazole. The composite preparation prepared according to the present invention allows rapid release of a drug without deteriorating its release by an interaction between mosapride and rabeprazole, thus exhibiting an improved drug release rate and bioavailability, while having excellent product stability and being capable of significantly lowering the amount of the excipient. Accordingly, the composite preparation of the present invention can improve patients' drug compliance due to the size of its dosage form.

  本发明涉及一种包含莫沙必利和雷贝拉唑的各种剂型的复合制剂。 根据本发明制备的复合制剂可使药物快速释放，而不会因莫沙必利和雷贝拉唑之间的相互作用而使药物释放恶化，从而显示出更高的药物释放率和生物利用度，同时具有优异的产品稳定性，并能够显著降低赋形剂的用量。因此，本发明的复合制剂由于剂型小，可以提高患者的服药依从性。
• Composite Preparation of Mosapride and Rabeprazole
  申请人：KOREA UNITED PHARM. INC.

  公开号：US20180177731A1

  公开（公告）日：2018-06-28

  The present invention relates to a composite preparation with various dosage forms comprising mosapride and rabeprazole. The composite preparation prepared according to the present invention allows rapid release of a drug without deteriorating its release by an interaction between mosapride and rabeprazole, thus exhibiting an improved drug release rate and bioavailability, while having excellent product stability and being capable of significantly lowering the amount of the excipient. Accordingly, the composite preparation of the present invention can improve patients' drug compliance due to the size of its dosage form.